DXCM · News · 20260804N
Litigation and Legal Risk
DEXCOM INC · 2026-08-04 · Importance 31 · Surprise 42 · In source text
Levi & Korsinsky filed a U.S. securities class action against DexCom on behalf of investors who purchased the company’s securities from January 8, 2024, through September 17, 2025. The complaint alleges that unauthorized design changes to DexCom’s G6 and G7 glucose-monitoring products reduced reliability and created health risks. It further alleges that DexCom’s public statements were materially false or misleading, with investors urged to contact counsel by December 26, 2025; the report does not disclose a damages amount or settlement value.
Key facts
- Levi & Korsinsky filed a securities class action against DexCom on behalf of investors who purchased securities between January 8, 2024 and September 17, 2025. source
- The lawsuit alleges unauthorized design changes to G6 and G7 that rendered them less reliable and posed health risks and alleges DexCom's public statements were materially false or misleading. source
- Investors were encouraged to contact Levi & Korsinsky by the December 26, 2025 deadline to explore potential recovery options. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| liability | negative | contingent | — | Levi & Korsinsky filed a securities class action against DexCom on behalf of investors who purchased securities between January 8, 2024… |